Skip to main content

RT @doctorRBC: Deucravacitinib: TYK2 inhibitor in pts with active SLE Phase 2, randomized, double blind, placebo-control

Social Author Name
Robert B Chao, MD
Tweet Content
Deucravacitinib: TYK2 inhibitor in pts with active SLE Phase 2, randomized, double blind, placebo-controlled study Met primary endpoint SRI response across all doses No death, MACE, VTE, systemic infections @RheumNow #EULAR2022 ABST#LB0004 https://t.co/yAM8qUZgee
Show on Archive Page
On
Display in Search Results
On
PDQ
Off